Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Disseminated intravascular coagulation future or investigational therapies

Introduction

Overview

Overview

Future or Investigational Therapies

Future or Investigational Therapies

  • Phase I trials suggest that infusion of activated protein C may also benefit patients with DIC.
    • The theory is that APC normally inactivates Va and VIIIa, resulting in a decrease in thrombin formation, and promotes fibrinolysis by inactivating plasminogen activator inhibitor.
  • Tissue factor pathway inhibitor has been shown to decrease mortality in baboon models of DIC with E. coli septic shock.
  • Agents such as ASA (aspirin), ticlopidine, dextran and GP IIb/IIIa inhibitors are also being examined with the goal of reducing platelet activation.
  • Currently, if fibrinolysis and hemorrhage appears to be more of a problem than clotting, the only options are antifibrinolytic agents, such as tranexamic acid. However, the risks of microvascular clot formation have limited its use.
References

References

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]